Continuous glucose monitoring (CGM) is a rapidly developing innovation poised to improve the lives of millions of people with diabetes. Providing vastly more information than today's episodic monitors, CGM can help patients achieve and sustain tight blood glucose control, which is critical in reducing long-term complications associated with the disease.
First-generation CGM devices are already available today for limited use. As the technology evolves, CGM is expected to become the new standard in daily monitoring, benefiting the almost three million people with diabetes on exclusive insulin therapy who must test their blood glucose levels several times per day. CGM devices also have the potential to become an important assessment and diagnostic tool for the remaining 10 million people with diabetes who test less frequently.
The GMSG analyzes the growing need for glucose monitoring tools, forecasts the technology's value, and initiates a discussion of the barriers that could impede its timely adoption. In addition, the GMSG promotes activities towards the development of an artificial pancreas.